Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pathological changes in prostate lesions after androgen manipulation

R Montironi1, C C Schulman

  • 1Institute of Pathological Anatomy and Histopathology, University of Ancona, Ospedale Regionale, Torrette, Italy. r.montironi@popcsi.unian.it

Journal of Clinical Pathology
|May 13, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erectile dysfunction and cardiovascular diseases.

Archivos espanoles de urologia·2010
Same author

To the German Society of Urology - centennial celebration.

Der Urologe. Ausg. A·2006
Same author

Bladder cancer: epidemiology, staging and grading, and diagnosis.

Urology·2006
Same author

Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.

Journal of clinical pathology·2006
Same author

Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens.

The Journal of urology·2005
Same author

Karyometry in the early detection and chemoprevention of intraepithelial lesions.

European journal of cancer (Oxford, England : 1990)·2005
Same journal

Measurement of microinvasive breast carcinoma in the 6th edition WHO Classification: risk of overstaging and clinical implications.

Journal of clinical pathology·2026
Same journal

Development and internal validation of a multifactorial risk model for predicting disease-free survival in oral squamous cell carcinoma.

Journal of clinical pathology·2026
Same journal

HER2-low as a unique subgroup in breast cancer: insights from neoadjuvant chemotherapy response and survival analysis.

Journal of clinical pathology·2026
Same journal

Polyp-forming Dieulafoy lesion of the rectum.

Journal of clinical pathology·2026
Same journal

Defining biochemical, pathological and molecular factors prognostic in terms of disease control and survival in high-grade extremity soft tissue sarcoma: a scoping review.

Journal of clinical pathology·2026
Same journal

MILGDF: a multi-task, instance-level supervised model for oral squamous cell carcinoma integrating local-global attention and dynamic decision fusion.

Journal of clinical pathology·2026
See all related articles

Neoadjuvant hormonal treatment may reduce positive surgical margins in prostate cancer patients, particularly those with clinical T2 tumors. However, its impact on downstaging and long-term survival remains uncertain, requiring further investigation.

Area of Science:

  • Oncology
  • Urology

Background:

  • Prostate cancer diagnoses are increasing due to an aging population and improved early detection awareness.
  • Clinical understaging and positive resection margins necessitate advanced management strategies.
  • Neoadjuvant hormonal treatment is explored to reduce tumor size and positive margins before definitive treatment.

Purpose of the Study:

  • To evaluate the effectiveness of neoadjuvant hormonal treatment in prostate cancer management.
  • To assess the impact of neoadjuvant hormonal therapy on pathological downstaging and surgical margin positivity.
  • To review the existing evidence on androgen manipulation prior to radical prostatectomy.

Main Methods:

  • Review of existing studies on neoadjuvant hormonal treatment for prostate cancer.

Related Experiment Videos

  • Analysis of pathological data regarding tumor downstaging and margin status.
  • Comparison of outcomes in clinical T2 and T3 tumors receiving neoadjuvant therapy.

    • Main Results:

    • Neoadjuvant treatment is associated with a 20-25% decrease in positive margins for clinical T2 tumors undergoing radical prostatectomy.
    • Evidence regarding pathological downstaging is conflicting, with some studies showing benefit and others none.
    • The effect of neoadjuvant treatment on positive margins in clinical T3 tumors is less clear.

    Conclusions:

    • Neoadjuvant hormonal treatment shows a consistent benefit in reducing positive surgical margins for localized prostate cancer (T2).
    • The impact on pathological downstaging and long-term outcomes like survival requires further long-term follow-up studies.
    • More research is needed to definitively establish the role of neoadjuvant hormonal therapy in altering metastatic spread and overall survival.